Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) have been assigned an average recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $60.40.

IMCR has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Immunocore from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Zacks Research raised shares of Immunocore from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a report on Thursday, January 22nd. UBS Group set a $55.00 target price on Immunocore and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Finally, Morgan Stanley upped their target price on Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th.

Immunocore Stock Performance

Shares of NASDAQ:IMCR opened at $32.05 on Monday. The firm has a 50 day moving average of $34.77 and a 200 day moving average of $34.39. The company has a quick ratio of 5.97, a current ratio of 6.00 and a debt-to-equity ratio of 0.99. The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of -56.23 and a beta of 0.78. Immunocore has a 52 week low of $23.15 and a 52 week high of $40.71.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.32. Immunocore had a negative return on equity of 7.67% and a negative net margin of 7.70%.The business had revenue of $103.69 million for the quarter, compared to the consensus estimate of $137.29 million. During the same period last year, the business posted $0.17 EPS. The business’s revenue was up 29.2% compared to the same quarter last year. On average, sell-side analysts predict that Immunocore will post -0.94 earnings per share for the current fiscal year.

Institutional Trading of Immunocore

Large investors have recently bought and sold shares of the stock. Bellevue Group AG raised its holdings in shares of Immunocore by 99.9% in the second quarter. Bellevue Group AG now owns 2,441,830 shares of the company’s stock worth $76,625,000 after buying an additional 1,220,036 shares during the last quarter. Primecap Management Co. CA lifted its position in Immunocore by 40.8% during the 2nd quarter. Primecap Management Co. CA now owns 3,771,474 shares of the company’s stock worth $118,349,000 after acquiring an additional 1,092,824 shares during the period. BVF Inc. IL purchased a new stake in Immunocore during the 2nd quarter valued at about $32,142,000. Millennium Management LLC increased its holdings in shares of Immunocore by 334.3% in the third quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock valued at $45,993,000 after purchasing an additional 974,463 shares during the period. Finally, Armistice Capital LLC raised its stake in shares of Immunocore by 21.5% in the third quarter. Armistice Capital LLC now owns 824,000 shares of the company’s stock worth $29,936,000 after purchasing an additional 146,000 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.